Molecular Oncology Program: Summary/Abstract The goal of the HDFCCC Molecular Oncology Program (MO) is to discover, develop, and translate novel preventive and therapeutic strategies and biomarkers. This is done through research that spans from basic science at the bench and computer to clinical applications and back, and by focusing on bridging the gap between scientists and clinical researchers, and from bench to start-up company to bedside. All MO Program activities reflect the HDFCCC’s cross-cutting themes of Impactful Discovery (Theme 1), Effective Translation (Theme 2), and Implementation and Dissemination (Theme 3) and are bolstered by the resources and collaborative environment provided by the HDFCCC. MO is a new research program since the prior competing renewal. The Center-wide realignment of research programs now allows MO members to interact around diagnostics and therapies focused on signaling pathways and epigenetics, as well as on therapies that are mutation-directed but tissue-agnostic, thus spanning multiple disciplines and connecting clinicians, epidemiologists, and basic scientists. Specifically, MO member research focuses on (1) studying the impact of genetics on cancer susceptibility, progression, and therapeutic response; (2) modulating signaling pathways for therapeutic benefit; and (3) developing tools and technologies to dissect tumor and host environment networks.